HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma.

Abstract
Live attenuated Listeria monocytogenes (LM) is a promising bacterial vector able to induce a T-cell response to tumor-associated antigens and demonstrates great potential for use in vaccine development. A novel recombinant LM-based vaccine (Lmdd (LM ΔdalΔdat)-MPFG (multiple peptide fusing genes)) was developed with the ability to express and secrete hepatocellular carcinoma (HCC)-related tumor-associated antigens fragments due to the insertion of hepatitis B virus (HBV)-X protein (HBx)-derived epitopes HBx(52-60) and HBx(140-148), the universal T-helper epitope, alpha-fetoprotein (AFP) epitope AFP(158-166), and melanoma antigen gene (MAGE)-3(271-279) into the HBV core protein. Following immunization with the Lmdd-MPFG vaccine, macrophages exhibited uptake of the bacteria; the vaccine was then nearly cleared 3 days after the first administration. It disappeared even more quickly following subsequent vaccinations. However, recombinant Lmdd-MPFG allowed for the full development of an antitumor response towards the human leukocyte antigen (HLA)-A0201 epitopes of MPFG. Each epitope stimulated an augmented T-cell proliferation and enhanced the supernatant level of interferon (IFN)-γ in vitro. In addition, IFN-γ-producing CD8(+) T cells as well as in vivo cytolytic activity were significantly increased in HLA-A2 transgenic mice. Additionally, the Lmdd-MPFG developed a strong antitumor response, as indicated by the significant resistance of immunized mice to MPFG-positive Hepa1-6 cell challenge in both a prophylactic and therapeutic setting. Tumor regression was accompanied by an enhanced cytotoxic T lymphocyte response and a decrease of regulatory T cells in the tumor. Collectively, these results suggest that utilizing attenuated LM as a vaccine vector, able to carry the MPFG gene, presents a potentially feasible strategy for prevention of HCC.
AuthorsY Chen, D Yang, S Li, Y Gao, R Jiang, L Deng, F R Frankel, B Sun
JournalOncogene (Oncogene) Vol. 31 Issue 17 Pg. 2140-52 (Apr 26 2012) ISSN: 1476-5594 [Electronic] England
PMID21927025 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Cancer Vaccines
  • DNA, Recombinant
  • Epitopes
  • Lmdd-MPFG vaccine
  • Trans-Activators
  • Viral Regulatory and Accessory Proteins
  • hepatitis B virus X protein
  • Interferon-gamma
Topics
  • Animals
  • Antigens, Neoplasm (immunology)
  • Cancer Vaccines (immunology, therapeutic use)
  • Carcinoma, Hepatocellular (immunology, therapy)
  • Cell Line, Tumor
  • DNA, Recombinant
  • Epitopes
  • Feasibility Studies
  • Humans
  • Interferon-gamma (metabolism)
  • Listeria monocytogenes (immunology)
  • Liver Neoplasms (immunology, therapy)
  • Lymphocyte Activation (immunology)
  • Mice
  • T-Lymphocytes (immunology)
  • Trans-Activators (immunology)
  • Transplantation, Heterologous
  • Viral Regulatory and Accessory Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: